Diaceutics (GB:DXRX)
LSE:DXRX
Top Page
Diaceutics
(LSE:DXRX)
Select Model
Select Model
Rating:57Neutral
Price Target:
175.00 p
▲(8.36% Upside)
Action:ReiteratedDate:12/07/25
Diaceutics' strong revenue growth and positive corporate events are overshadowed by challenges in profitability, cash flow, and bearish technical indicators. The stock's valuation is also concerning due to negative earnings.
Positive Factors
Revenue Growth
Sustained double-digit revenue growth reflects rising demand for Diaceutics' diagnostic-pathway and commercialization services. Over a multi-quarter horizon this supports scale advantages, deeper pharma partnerships, and the ability to convert analytics IP into recurring multi-year contracts, strengthening long-term revenue visibility.
Negative Factors
Profitability
Persistent negative net and EBIT margins indicate operating costs and non-operating charges erode reported profitability despite EBITDA strength. Over months this constrains retained earnings, limits reinvestment capacity, and requires sustained margin improvement to convert revenue growth into durable bottom-line gains.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained double-digit revenue growth reflects rising demand for Diaceutics' diagnostic-pathway and commercialization services. Over a multi-quarter horizon this supports scale advantages, deeper pharma partnerships, and the ability to convert analytics IP into recurring multi-year contracts, strengthening long-term revenue visibility.
Read all positive factors
Diaceutics (DXRX) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£132.39M
Dividend YieldN/A
Average Volume (3M)79.63K
Price to Earnings (P/E)―
Beta (1Y)0.44
Revenue Growth31.83%
EPS Growth46.59%
CountryUK
Employees184
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)N/A
Shares Outstanding84,917,280
10 Day Avg. Volume58,068
30 Day Avg. Volume79,634
Financial Highlights & Ratios
PEG Ratio25.77
Price to Book (P/B)2.66
Price to Sales (P/S)3.30
P/FCF Ratio-26.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£215.00Price Target Upside33.13% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Diaceutics Business Overview & Revenue Model
Company Description
Diaceutics PLC, a diagnostic commercialization company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It operates DXRX platform, which offers DXRX data solutions, including access to various pip...
How the Company Makes Money
Diaceutics generates revenue through a combination of subscription fees, consulting services, and data analytics solutions. The company offers a subscription-based model for its DXRX platform, where pharmaceutical companies pay for access to advan...
Diaceutics Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
70
Positive
Cash Flow
60
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 34.40M | 32.16M | 23.70M | 19.50M | 13.94M | 12.70M |
| Gross Profit | 29.63M | 28.27M | 19.71M | 14.04M | 10.57M | 9.33M |
| EBITDA | 2.69M | 2.77M | 2.36M | 3.61M | 2.35M | 178.00K |
| Net Income | -1.52M | -1.70M | -1.75M | 724.00K | 561.00K | 263.00K |
Balance Sheet | ||||||
| Total Assets | 44.42M | 48.62M | 46.34M | 48.26M | 45.01M | 43.52M |
| Cash, Cash Equivalents and Short-Term Investments | 10.38M | 12.74M | 16.67M | 19.84M | 19.68M | 25.25M |
| Total Debt | 1.13M | 1.06M | 1.21M | 1.33M | 1.56M | 118.00K |
| Total Liabilities | 7.18M | 8.76M | 5.56M | 5.74M | 4.36M | 3.28M |
| Stockholders Equity | 37.24M | 39.86M | 40.79M | 42.51M | 40.65M | 40.24M |
Cash Flow | ||||||
| Free Cash Flow | 10.00K | -3.98M | -3.54M | 278.00K | -5.03M | -6.04M |
| Operating Cash Flow | 104.00K | 651.00K | 1.31M | 5.15M | 570.00K | 253.00K |
| Investing Cash Flow | -5.76M | -4.03M | -4.21M | -4.87M | -5.60M | -6.29M |
| Financing Cash Flow | -242.00K | -64.00K | -239.00K | -132.00K | -270.00K | 19.61M |
Diaceutics Technical Analysis
Positive
161.50
Price Trends
155.46
Negative
150.75
Negative
146.22
Positive
Market Momentum
-1.58
Negative
57.64
Neutral
66.03
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:DXRX, the sentiment is Positive. The current price of 161.5 is above the 20-day moving average (MA) of 145.55, above the 50-day MA of 155.46, and above the 200-day MA of 146.22, indicating a neutral trend. The MACD of -1.58 indicates Negative momentum. The RSI at 57.64 is Neutral, neither overbought nor oversold. The STOCH value of 66.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:DXRX.
Diaceutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | £105.16M | 55.78 | 3.01% | ― | -1.43% | 28.57% | |
57 Neutral | £132.39M | -5.17 | -3.95% | ― | 31.83% | 46.59% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | £10.23M | -1.31 | -104.73% | ― | 29.64% | 28.51% | |
47 Neutral | £15.25M | -1.51 | -153.92% | ― | 90.42% | 79.21% | |
40 Underperform | £8.58M | -0.25 | -316.67% | ― | 72.17% | 79.03% | |
39 Underperform | £9.18M | ― | 425.97% | ― | -4.48% | 61.09% |
* Healthcare Sector Average
GB:DXRX
Diaceutics
156.50
38.50
32.63%
GB:CLBX
ANGLE plc
0.90
-8.60
-90.53%
GB:EKF
EKF Diagnostics Holdings
24.40
1.10
4.72%
GB:GDR
Genedrive
0.95
-0.54
-36.33%
GB:OBD
Oxford BioDynamics
0.20
-0.25
-55.56%
GB:RENX
Renalytix
2.10
-6.90
-76.67%
Diaceutics Corporate Events
Business Operations and StrategyRegulatory Filings and Compliance
Diaceutics Issues New Shares to Trust as PDMRs Participate in Incentive Plan
Neutral
Feb 3, 2026
Diaceutics PLC has disclosed that trustees of its 2020 Employee Benefit Trust have purchased ordinary shares on behalf of three senior executives under the company’s UK and Global Share Incentive Plan, with the company matching these purchas...
Business Operations and StrategyFinancial Disclosures
Diaceutics Returns to Profit as Recurring Revenues and Order Book Hit Record Highs
Positive
Jan 15, 2026
Diaceutics reported an estimated 20% rise in 2025 revenues to £38.5 million, a return to profitability and a roughly 75% jump in adjusted EBITDA, underpinned by strong demand for its precision medicine commercialisation platform and greater a...
Business Operations and StrategyRegulatory Filings and Compliance
Diaceutics Issues Shares to Trust Under Ongoing Incentive Plan, Updates Total Voting Rights
Neutral
Dec 23, 2025
Diaceutics has reported that the trustees of its Global 2020 Employee Benefit Trust have been purchasing ordinary shares on behalf of several senior managers under the company’s UK and Global Share Incentive Plan, with these purchases set to...
Business Operations and Strategy
Diaceutics PLC Expands Employee Share Incentive Plan
Positive
Nov 28, 2025
Diaceutics PLC has announced that trustees of its 2020 Employee Benefit Trust have purchased ordinary shares on behalf of certain key personnel as part of the company’s UK and Global Share Incentive Plan. These purchases, matched by the comp...
Business Operations and Strategy
Diaceutics PLC Enhances Employee Engagement with Share Incentive Plan
Positive
Nov 4, 2025
Diaceutics PLC has announced that its trustees have purchased ordinary shares on behalf of key personnel as part of the company’s Share Incentive Plan (SIP) for employees. This initiative, which involves matching employee share purchases wit...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.